189 – The AUTOSTEM platform for closed manufacture of bone marrow-derived mesenchymal stromal cells using a closed, scalable and automated robotic system

The cost of age-related chronic diseases like diabetes and osteoporosis with associated bone repair issues is huge and set to increase significantly with ageing populations. Cell therapy aims to address this global problem by providing a long-term solution for the effective treatment of damaged tissue via biological tissue regeneration or protection. Mesenchymal stem/stromal cells (MSCs) isolated from various tissues are in advanced clinical testing for a number of indications and are slowly entering clinical use for the repair/regeneration of a range of damaged tissues. However, a major challenge in the field is the economically viable production of therapeutic quantities of GMP MSCs.